Target intelligence / Profile preview

N-terminal asparagine amidase pseudogene 3 (NTAN1P3)

Target
NTAN1P3
Molecular classification
Pseudogene, Long non-coding RNA (subset: processed/unprocessed, possible function as lncRNA)
01

Overview

N-terminal asparagine amidase pseudogene 3 (NTAN1P3) is a pseudogene—defined as a DNA sequence similar to a functional gene but typically incapable of encoding a functional protein product. NTAN1P3 is classified in human genomic databases as a pseudogene and, like most pseudogenes, is not considered a therapeutic target because it does not encode a functional protein, receptor, or enzyme. Pseudogenes can sometimes act as regulators of gene expression—usually through acting as decoys for microRNAs or producing regulatory noncoding RNAs—but NTAN1P3 specifically has no known function, no disease link, and no established role as a biomarker, target, or safety concern. Its biological importance, if any, remains undemonstrated[3][2][1]. Notes: - NTAN1P3 is not an active enzyme, receptor, transporter, or protein-coding gene. - As a pseudogene, it is not considered a therapeutic target. - No known drugs, biomarkers, or safety aspects are associated. - The target is *not* misspelled, but its classification as a target is incorrect, as it is not a functional or druggable molecule[3].

Other names
NTAN1P3
02

Biological functions

Potential regulation of coding gene expression via RNA interference pathways (e.g., as siRNA or miRNA decoy), but no direct protein product or enzyme activity
03

Disease associations

Other (pseudogenes have been implicated in cancer via regulatory mechanisms in a few cases; no disease directly associated with NTAN1P3)

Beyond the preview

Go deeper on N-terminal asparagine amidase pseudogene 3 (NTAN1P3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-terminal asparagine amidase pseudogene 3 (NTAN1P3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call